The use of macrolides in the 2009 H1N1 virus infection outbreak: A survey of general practices in Japan

Respiratory Investigation

Volumn 51, Issue 4, 2013, Pages 257-259

  Azuma, Arata ^a   Yamaya, Mutsuo ^b   Kadota, Jun ichi ^c   Mikasa, Keiichi ^d   Kudoh, Shoji ^e  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OITA UNIVERSITY   (Japan)

^d NARA MEDICAL UNIVERSITY   (Japan)

^e Japan Anti tuberculosis Association   (Japan)

Author keywords

Antibiotics; Macrolides; Pandemic influenza virus; Physician

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; CEFCAPENE; CLARITHROMYCIN; LEVOFLOXACIN; MACROLIDE;

2009 H1N1 INFLUENZA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; EPIDEMIC; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; JAPAN; MAJOR CLINICAL STUDY; PRESCRIPTION; RETROSPECTIVE STUDY;

ANTIBIOTICS; MACROLIDES; PANDEMIC INFLUENZA VIRUS; PHYSICIAN;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; COINFECTION; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; JAPAN; MACROLIDES; PHYSICIAN'S PRACTICE PATTERNS; PNEUMONIA, BACTERIAL; PRESCRIPTIONS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84887623444     PISSN: 22125345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resinv.2013.04.002     Document Type: Article

References (10)

1. Brundage J.F. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006, 6:303-312.
2. Perez-Padilla R., de la Rosa-Zamboni D., Ponce de Leon S., et al. INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009, 361:680-689.
3. Yamaya M., Azuma A., Takizawa H., et al. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012, 40:485-494.
4. Ikematsu H., Hirotsu N., Kawai N., et al. The effectiveness of clarithromycin for clearing the respiratory symptoms of influenza patients treated with oseltamivir or zanamivir [English Abstract]. Antibiot Chemother 2008, 24:78-84.
5. Ishii H., Komiya K., Yamagata E., et al. Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection. J Infect 2012, 64:343-345.
6. Morens D.M., Taubenberger J.K., Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008, 198:962-970.
7. Soler-Cataluña J.J., Martinez-Garcia M.A., Roman Sanchez P., et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:925-931.
8. Suzuki T., Yanai M., Yamaya M., et al. Erythromycin and common cold in COPD. Chest 2001, 120:730-733.
9. Seemungal T.A., Wilkinson T.M., Hurst J.R., et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008, 178:1139-1147.
10. Wright P.F., Kirkland K.B., Modlin J.F., et al. When to consider the use of antibiotics in the treatment of 2009 H1N1 influenza-associated pneumonia. N Engl J Med 2009, 361:e112.